

Partnership. Innovation. Passion.

16th May, 2024

To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 To, The Manager – Listing, National Stock Exchange of India Ltd., Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: GLS

Dear Sir/Madam,

<u>Sub:</u> Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) <u>Regulations, 2015 – Intimation of Investors/Analyst Meeting</u>

With reference to the captioned subject and pursuant to Regulation 30 and Para A of Part A of Schedule III of SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015, please find below details of the meeting with Investor/Analyst which will be attended by the representatives of the Company.

Date	Name	Mode
May 22, 2024	Polar Capital	In person

The schedule and mode of meeting may undergo a change due to exigencies on part of the Investor/Analyst/Company.

You are requested to kindly take a note of the same.

Thanking You,

Your Sincerely,

For Glenmark Life Sciences Limited

Rudalf Corriea Company Secretary and Compliance Officer

Glenmark Life Sciences Limited

Corporate Office: 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai 400 099, India. Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur - 413 213, India. T: 91 22 68297979 CIN: L74900PN2011PLC139963 E: complianceofficer@glenmarklifesciences.com W: www.glenmarklifesciences.com